Stock Traders Purchase Large Volume of Call Options on Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) saw some unusual options trading on Monday. Investors bought 7,643 call options on the company. This represents an increase of 1,707% compared to the typical volume of 423 call options.

Insider Activity

In related news, insider Donald Notman sold 6,301 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $7.84, for a total transaction of $49,399.84. Following the sale, the insider now directly owns 204,563 shares in the company, valued at $1,603,773.92. This trade represents a 2.99 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Pravin Dugel sold 21,475 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the transaction, the insider now owns 3,520,318 shares of the company's stock, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,895 shares of company stock worth $283,772. Insiders own 3.50% of the company's stock.

Institutional Trading of Ocular Therapeutix

Several large investors have recently bought and sold shares of the company. Deep Track Capital LP boosted its holdings in Ocular Therapeutix by 0.9% in the fourth quarter. Deep Track Capital LP now owns 12,836,282 shares of the biopharmaceutical company's stock worth $109,622,000 after acquiring an additional 114,822 shares in the last quarter. Vanguard Group Inc. raised its stake in Ocular Therapeutix by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company's stock valued at $72,453,000 after buying an additional 99,730 shares during the last quarter. Point72 Asset Management L.P. increased its position in Ocular Therapeutix by 43.9% during the fourth quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company's stock valued at $25,073,000 after acquiring an additional 895,304 shares during the last quarter. Deltec Asset Management LLC lifted its stake in shares of Ocular Therapeutix by 0.6% in the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company's stock worth $22,344,000 after purchasing an additional 16,300 shares during the period. Finally, Braidwell LP raised its position in Ocular Therapeutix by 36.3% in the third quarter. Braidwell LP now owns 2,239,770 shares of the biopharmaceutical company's stock worth $19,486,000 after acquiring an additional 596,000 shares during the period. 59.21% of the stock is owned by institutional investors.

Remove Ads

Ocular Therapeutix Stock Performance

Shares of OCUL stock traded up $0.19 during trading on Thursday, reaching $7.34. 1,504,273 shares of the company's stock traded hands, compared to its average volume of 1,562,781. Ocular Therapeutix has a 1 year low of $4.06 and a 1 year high of $11.78. The firm's 50-day moving average is $7.78 and its 200 day moving average is $8.88. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $1.15 billion, a P/E ratio of -5.56 and a beta of 1.22.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The business had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. Equities research analysts expect that Ocular Therapeutix will post -0.98 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $17.00.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.